Lower irritation microemulsion-based rotigotine gel: Formulation optimization and in vitro and in vivo studies

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 633-644

  Wang, Zheng ^a   Mu, Hong Jie ^a   Zhang, Xue Mei ^a   Ma, Peng Kai ^a   Lian, Sheng Nan ^a   Zhang, Feng Pu ^a   Chu, Sheng Ying ^a   Zhang, Wen Wen ^a   Wang, Ai Ping ^a,b   Wang, Wen Yan ^b   Sun, Kao Xiang ^a  

^a YANTAI UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery System   (China)

Author keywords

Central composite design; Pseudoternary phase diagrams; Transdermal

Indexed keywords

CARBOMER; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; LABRASOL; ROTIGOTINE; WATER; WATER OIL CREAM; DRUG CARRIER; EMULSION; HYDROGEL; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG PENETRATION; FEMALE; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; PATIENT COMPLIANCE; SKIN IRRITATION; SKIN PERMEABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; TRANSDERMAL PATCH; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; EMULSION; PHARMACOKINETICS; RAT; SKIN; TOPICAL DRUG ADMINISTRATION;

RATTUS;

ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; EMULSIONS; HYDROGEL; RATS; SKIN; SKIN IRRITANCY TESTS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84921527741     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S74079     Document Type: Article

References (17)

1. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73-86.
2. Swart PJ, De Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie. 1992;47(8):613-615.
3. Calabrese VP, Lloyd KA, Brancazio P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov Disord. 1998;13(5):768-774.
4. Antonini A, Bernardi L, Calandrella D, Mancini F, Plebani M. Rotigotine transdermal patch in the management of Parkinson’s disease (PD) and its night-time use for PD-related sleep disorders. Funct Neurol. 2010;25(1):21-25.
5. Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 2010;388(1-2):231-241.
6. Salimi A, Sharif Makhmal Zadeh B, Moghimipour E. Preparation and characterization of cyanocobalamin (vit B12) microemulsion properties and structure for topical and transdermal application. Iran J Basic Med Sci. 2013;16(7):865-872.
7. Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2006;315(1-2):52-58.
8. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89-121.
9. Chen H, Mou D, Du D, et al. Hydrogel-thickened microemulsion for topical administration of drug molecule at an extremely low concentration. Int J Pharm. 2007;341(1-2):78-84.
10. El-Sherbiny IM, Yacoub MH. Hydrogel scaffolds for tissue engineering: Progress and challenges. Glob Cardiol Sci Pract. 2013;2013(3):316-342.
11. Moghimipour E, Salimi A, Karami M, Isazadeh S. Preparation and characterization of dexamethasone microemulsion based on pseudoternary phase diagram. Jundishapur J Nat Pharm Prod. 2013;8(3):105-112.
12. Panapisal V, Charoensri S, Tantituvanont A. Formulation of microemulsion systems for dermal delivery of silymarin. AAPS Pharm Sci Tech. 2012;13(2):389-399.
13. Hayton WL, Chen T. Correction of perfusate concentration for sample removal. J Pharm Sci. 1982;71(7):820-821.
14. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233-246.
15. Delongeas JL, de Conchard GV, Beamonte A, et al. Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats. Regul Toxicol Pharmacol. 2010;57(2-3):284-290.
16. Zhang Y, Wang Y, Wang ZG, et al. Optimization of fermentation medium for the production of atrazine degrading strain Acinetobacter sp. DNS(32) by statistical analysis system. J Biomed Biotechnol. 2012;2012: 623062.
17. Mahdi ES, Sakeena MH, Abdulkarim MF, Abdullah GZ, Sattar MA, Noor AM. Effect of surfactant and surfactant blends on pseudoternary phase diagram behavior of newly synthesized palm kernel oil esters. Drug Des Devel Ther. 2011;5:311-323.